三甘油和葡萄糖指数:与胰岛素耐药性同居模式评估相比的成本效益分析
Armando Nevárez-Sida1, Fernando Guerrero-Romero1
1Biomedical Research Unit, Mexican Social Security Institute, Durango/Dgo, Mexico.
Value in health regional issues
|June 14, 2023
概括
甘油三和葡萄糖指数 (TyG) 是一种更具成本效益和有效的胰岛素抵抗的诊断工具,与胰岛素抵抗指数 (HOMA-IR) 的同源模式评估相比. TyG测试显著更便宜,更准确.
科学领域:
- 内分泌学和新陈代谢学
- 诊断准确性研究 诊断准确性研究
- 卫生经济学 卫生经济学
背景情况:
- 胰岛素抵抗 (IR) 是代谢障碍的一个关键因素.
- 准确和经济有效的IR诊断方法对于及时干预至关重要.
- 像HOMA-IR这样的现有方法在成本和有效性方面存在局限性.
研究的目的:
- 将甘油三和葡萄糖 (TyG) 指数的成本效益与用于诊断胰岛素耐药性的胰岛素耐药性 (HOMA-IR) 均质模型评估进行比较.
- 评估诊断准确度指标,包括两种指标的灵敏度,特异性和成本效益比率.
主要方法:
- 一个决策树模型被用于成本效益分析.
- 计算了TyG和HOMA-IR的平均和增量成本效益比率.
- 进行单向灵敏度分析和蒙特卡洛模拟进行概率分析.
主要成果:
- 泰格指数表现出卓越的成本效益,每次测试的成本为1.64美元,而HOMA-IR的成本为4.26美元.
- 在真阳性 (0.77对0.74) 和真阴性 (0.17对0.15) 测试中,TyG的有效性更高.
- 使用TyG诊断IR的成本比使用HOMA-IR低61.5%.
结论:
- 泰格指数是诊断胰岛素耐药性的高效和低成本替代方案.
- 与HOMA-IR相比,TyG在准确性和经济效率方面提供了显著的优势.
相关概念视频
Oral Hypoglycemic Agents: Biguanides and Glitazones
240
Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood...
240
Glucose Homeostasis: Regulation of Blood Glucose
1.8K
Carbohydrates consumed through foods are converted into glucose, a crucial energy source for the body. In the prandial state, high blood glucose levels stimulate the secretion of insulin from the pancreas. Insulin inhibits hepatic glucose production and stimulates glucose uptake and metabolism by muscle and adipose tissue. The excess glucose is converted into glycogen and stored in the liver and muscles.
During fasting, when blood glucose levels are low, the pancreas secretes glucagon. it...
During fasting, when blood glucose levels are low, the pancreas secretes glucagon. it...
1.8K
Hormones Regulating Blood Glucose
3.6K
Insulin is released by beta cells of the pancreas when blood glucose levels are high. It facilitates glucose absorption and utilization in insulin-dependent cells with insulin receptors on their plasma membranes. Insulin promotes glucose uptake by increasing the number of glucose transport proteins in the cell membrane, allowing glucose to enter the cell. As a result, glucose utilization and ATP production are enhanced.
In addition to accelerating glucose uptake and utilization, insulin has...
In addition to accelerating glucose uptake and utilization, insulin has...
3.6K
Insulin: Dosing Regimen and Adverse Effects
215
Insulin-replacement therapy usually includes both long-acting insulin (basal) and short-acting insulin (to cater to postprandial needs). In a diverse group of type 1 diabetes patients, the average daily insulin dose is typically 0.5-0.7 units/kg body weight. However, obese patients and pubertal adolescents may need more due to insulin resistance.
The basal dose constitutes about 40%-50% of the total daily dose, with the rest as premeal insulin. The mealtime insulin dose should mirror...
The basal dose constitutes about 40%-50% of the total daily dose, with the rest as premeal insulin. The mealtime insulin dose should mirror...
215
Glucose Homeostasis: Pancreatic Islets and Insulin Secretion
1.3K
The pancreatic islets comprising only 1%-2% of the volume are highly vascularized and innervated mini-organs. They contain five endocrine cell types, including β cells that secrete insulin, which is synthesized as a single polypeptide chain, preproinsulin, processed to proinsulin, and finally to insulin and C-peptide. This process is complex and regulated, involving the Golgi complex, the endoplasmic reticulum, and the secretory granules of the β cell.
Insulin and C-peptide are...
Insulin and C-peptide are...
1.3K
Diabetes: Management and Pharmacotherapy
319
The therapy for diabetes aims to alleviate hyperglycemia-related symptoms, prevent acute metabolic decompensation, and reduce chronic end-organ complications. Glycemic control is evaluated through short-term (self-monitoring, continuous glucose monitoring) and long-term (A1c, fructosamine) metrics, enabling near real-time tracking of blood glucose levels and reflecting glycemic control over specific time frames.
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
319


